Summit Therapeutics (SMMT) Share-based Compensation (2017 - 2026)

Summit Therapeutics (SMMT) has reported Share-based Compensation for 10 consecutive years, with $68.7 million the latest figure, recorded in Q2 2026.

• Quarterly Share-based Compensation fell 85.65% year-over-year to $68.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $384.0 million (down 26.18% YoY) and the FY2025 annual result came in at $732.4 million, up 1336.65% from the prior year.
• Share-based Compensation eased to $68.7 million in Q2 2026 per SMMT's latest filing, from $72.8 million in the prior quarter.
• Over the last five years, Share-based Compensation for SMMT reached as high as $478.8 million in Q2 2025 and fell as low as $705000.0 in Q3 2023.
• A 5-year average of $53.0 million and a median of $10.3 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2025 — Share-based Compensation soared 4218.04% — and 2026, when it plunged 85.65%.
• Year by year, Share-based Compensation stood at $2.7 million in 2022, then jumped by 229.31% to $8.8 million in 2023, then increased by 25.84% to $11.0 million in 2024, then surged by 914.79% to $111.8 million in 2025, then slumped by 38.53% to $68.7 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $68.7 million, $72.8 million, and $111.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.